公开(公告)号：EP0752869B1

公开(公告)日：2001-07-18

申请号：EP95914995.6

申请日：1995-03-30

申请人： DIACRIN, INC.

发明人： CHAPPEL, Scott, C.

IPC分类号： A61K35/39 ,  A61K35/407 ,  A61K35/30 ,  A61K35/34 ,  A61K35/28

CPC分类号： C07K16/2833 ,  A61K35/12 ,  A61K35/28 ,  A61K35/30 ,  A61K35/34 ,  A61K35/39 ,  A61K35/407 ,  A61K2035/122 ,  A61K2039/505 ,  C07K2317/54 ,  C12N5/0676

摘要： Cells suitable for transplantation which have at least two different epitopes on a surface antigen altered prior to transplantation to inhibit rejection of the cells following transplantation into an allogeneic or xenogeneic recipient are disclosed. These cells are more successfully transplanted than cells which have only a single epitope on the surface antigen altered. Preferably, the antigen on the cell surface which is altered is an MHC class I antigen. Two different epitopes on an MHC class I antigen can be altered by contacting the cell with two molecules, such as antibodies or fragments thereof (e.g., F(ab')2 fragments), which bind to two different epitopes on the antigen. Preferred epitopes on human MHC class I antigens to be altered are epitopes recognized by the monoclonal antibodies W6/32 and PT85. Improved methods for transplantation utilizing cells which have at least two different epitopes on a surface antigen altered prior to transplantation are also disclosed.

公开(公告)号：EP0752869A1

公开(公告)日：1997-01-15

申请号：EP95914995.0

申请日：1995-03-30

申请人： DIACRIN, INC.

发明人： CHAPPEL, Scott, C.

IPC分类号： A61K35 ,  C07K16 ,  C12N5

CPC分类号： C07K16/2833 ,  A61K35/12 ,  A61K35/28 ,  A61K35/30 ,  A61K35/34 ,  A61K35/39 ,  A61K35/407 ,  A61K2035/122 ,  A61K2039/505 ,  C07K2317/54 ,  C12N5/0676

摘要： Cells suitable for transplantation which have at least two different epitopes on a surface antigen altered prior to transplantation to inhibit rejection of the cells following transplantation into an allogeneic or xenogeneic recipient are disclosed. These cells are more successfully transplanted than cells which have only a single epitope on the surface antigen altered. Preferably, the antigen on the cell surface which is altered is an MHC class I antigen. Two different epitopes on an MHC class I antigen can be altered by contacting the cell with two molecules, such as antibodies or fragments thereof (e.g., F(ab')2 fragments), which bind to two different epitopes on the antigen. Preferred epitopes on human MHC class I antigens to be altered are epitopes recognized by the monoclonal antibodies W6/32 and PT85. Improved methods for transplantation utilizing cells which have at least two different epitopes on a surface antigen altered prior to transplantation are also disclosed.

公开(公告)号：EP0751987A1

公开(公告)日：1997-01-08

申请号：EP95915498.0

申请日：1995-03-30

申请人： DIACRIN, INC.

发明人： EGAN, E., Michael ,  CHAPPEL, Scott, C.

IPC分类号： A61K35 ,  A61K39 ,  C07K16 ,  A61K48

CPC分类号： C07K16/2833 ,  A61K35/34 ,  A61K39/001 ,  A61K48/00 ,  A61K2039/5156

摘要： Cells suitable for transplantation which can be used to deliver a gene product to an allogeneic or xenogeneic subject are disclosed. Such cells are modified to express a gene product and have at least one antigen on the cell surface which stimulates an immune response against the cell in an allogeneic or xenogeneic subject. Prior to administration of the modified cells, the antigen on the cell surface, such as an MHC class I antigen, is altered to inhibit rejection of the cell by an allogeneic or xenogeneic subject. Preferably, the antigen is altered by contact with an antibody, or fragment or derivative thereof, such as an F(ab)'2 fragment. Alteration of the antigen on the surface of the cells prior to administration inhibits immunological rejection of the cells and avoids the need for systemic immunosuppression of a subject.